Abstract
Background and objectives Paediatric tuberculosis (TB) remains a major public health concern in high-burden settings like the Western Cape (WC), South Africa. We analysed geographic differences in TB burden among children and adolescents, described temporal trends, and quantified gaps in the TB care cascade.
Methods We analysed TB episodes recorded in the WC Provincial Health Data Centre (PHDC) from 2017-2023, stratified by 5-year age groups, and compared them to adult episodes. We assessed HIV status, drug resistance status, microbiological testing, disease classification, place of diagnosis, and TB treatment outcomes. Reporting gaps were estimated by comparing PHDC-recorded episodes to national notifications. Incidence rates were calculated using mid-year population estimates.
Results In 2023, TB incidence rates of diagnosis in the WC were 722.4, 189.1, 171.2, and 523.4 per 100,000 population ages 0-4, 5-9, 10-14, and 15-19 years. Children aged 0-4 years accounted for 47.9% of paediatric TB episodes. In the Cape Winelands district in 2023, TB incidence among 0-4-year-olds was double that of adults in the district and 2-4 times higher than 0-4-year-olds in other districts. Among PHDC-recorded episodes, 17.3% were not reported at national level. Treatment success was low, with only 70.3% of diagnosed children and adolescents completing treatment in 2023.
Conclusions Our findings highlight geographic variation in paediatric TB burden in the WC, emphasizing the need to address local drivers to inform targeted interventions. Gaps in the paediatric TB care cascade remain major concerns. Strengthening integrated data systems beyond TB treatment registers, could improve surveillance, health system planning, and patient outcomes.
Article summary Using comprehensive provincial data, this study captures high TB incidence in young children, geographic variation in diagnosis, care cascade losses, and underreporting in routine surveillance.
What’s Known on This subject TB among children and adolescents remains a major public health concern in high-burden settings like the Western Cape. Improved understanding of local epidemiology and integrated data systems could assist in strengthening surveillance, guiding interventions, and improving outcomes for paediatric TB.
What This Study Adds Analysis of microbiologically confirmed and clinically diagnosed TB in the Western Cape (2017-2023) revealed high incidence among young children, substantial losses across the care cascade, geographic heterogeneity in diagnosis, and underreporting, highlighting the value of integrated data for improved surveillance.
Contributors statement Lauren R Brown conceptualized the study, conducted the formal analysis and investigation, designed the methodology, wrote the original draft and edited the final manuscript.
Mariette Smith conceptualized the study, designed the methodology, and extracted the original dataset.
Dr Cari van Schalkwyk and Dr Karen du Preez conceptualized the study, designed the methodology, and reviewed and edited the final manuscript.
Prof Leigh Johnson, Vanessa Mudaly, Erika Mohr-Holland, Prof H. Simon Schaaf, Prof James A. Seddon, Prof Anneke C. Hesseling, Prof James Nuttall, Prof Helena Rabie, Prof Mary-Ann Davies, and Prof Andrew Boulle reviewed and edited the final manuscript.
All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the Fogarty International Center of the US National Institutes of Health [K43TW011006 K.d.P] and the Bill & Melinda Gates Foundation [INV063625 L.R.B., C.v.S., and L.F.J.]. These funders had no role in the design and conduct of the study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Conflict of interest disclosures: The authors have no conflicts of interest relevant to this article to disclose.
Funding/support: This work was supported by the Fogarty International Center of the US National Institutes of Health [K43TW011006 K.d.P] and the Bill & Melinda Gates Foundation [INV063625 L.R.B., C.v.S., and L.F.J.]. These funders had no role in the design and conduct of the study.
Author contributions updated to reflect work related to the manuscript.
Data Availability
All data analysed in the present work are contained in the manuscript and supplementary material
Abbreviations
- TB
- tuberculosis
- HIV
- Human Immunodeficiency Virus
- WC
- Western Cape
- CAWTB
- children and adolescents with TB
- PHDC
- Provincial Health Data Centre
- (E)PTB
- (extra)pulmonary TB
- (I)LTFU
- (initial) loss to follow-up